Q1 Earnings Estimate for Repligen Issued By Leerink Partnrs

Repligen Co. (NASDAQ:RGEN) – Equities research analysts at Leerink Partnrs dropped their Q1 2025 earnings estimates for Repligen in a report issued on Thursday, February 20th. Leerink Partnrs analyst P. Souda now anticipates that the biotechnology company will earn $0.35 per share for the quarter, down from their prior estimate of $0.39. The consensus estimate for Repligen’s current full-year earnings is $1.72 per share. Leerink Partnrs also issued estimates for Repligen’s Q4 2025 earnings at $0.51 EPS, FY2025 earnings at $1.72 EPS and FY2026 earnings at $2.33 EPS.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The firm had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%.

RGEN has been the subject of several other reports. TD Cowen initiated coverage on shares of Repligen in a research note on Monday, February 10th. They set a “buy” rating and a $200.00 target price for the company. Canaccord Genuity Group started coverage on shares of Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $180.00 target price on shares of Repligen in a research report on Friday, February 21st. Royal Bank of Canada boosted their price objective on shares of Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research note on Friday, February 21st. Finally, JPMorgan Chase & Co. upped their price target on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $181.00.

Repligen Stock Performance

Shares of NASDAQ RGEN opened at $161.47 on Monday. The stock has a market cap of $9.05 billion, a PE ratio of -316.61, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99. The firm has a fifty day moving average price of $155.30 and a 200-day moving average price of $148.57. Repligen has a 1 year low of $113.50 and a 1 year high of $203.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Institutional Investors Weigh In On Repligen

A number of hedge funds have recently modified their holdings of the business. Champlain Investment Partners LLC increased its position in Repligen by 149.0% during the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after purchasing an additional 850,345 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Repligen by 11.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock valued at $1,027,165,000 after purchasing an additional 743,815 shares during the period. Point72 Asset Management L.P. boosted its stake in shares of Repligen by 183.1% in the fourth quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company’s stock valued at $132,227,000 after purchasing an additional 594,189 shares during the period. Groupama Asset Managment lifted its stake in Repligen by 12,321.0% in the fourth quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company’s stock worth $58,142,000 after acquiring an additional 400,680 shares during the last quarter. Finally, Alyeska Investment Group L.P. acquired a new stake in Repligen during the fourth quarter worth approximately $53,428,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.